Highlighted Data

Recent Clinical Data Presentations

Macula Society 2022 — ADVM-022 Clinical Data
Improved Anatomical Outcomes in ADVM-022 Treated Subjects Relative to Standard-of-Care Bolus Anti-VEGF Therapy: Results From the Phase 1 Study of Intravitreal (IVT) Gene Therapy with ADVM-022 for Neovascular AMD (OPTIC Trial)

ASGCT 2022 — ADVM-022 Clinical Data
The OPTIC Study of Intravitreal Gene Therapy with ADVM-022 for Neovascular AMD (nAMD): The Role of Neutralizing Antibodies

ARVO 2022 — ADVM-022 Clinical Data
New Data from the OPTIC Trial of ADVM-022: Role of Neutralizing Antibodies

ASGCT 2022 – LSV1 — Pipeline Preclinical Data
Novel Capsid LSV1 Has a Unique 3D Structure at the Loop Substitution Area - Confers Superior Retinal Transduction from Intravitreal Injection

ASGCT 2022 – AAV.7m8 Platform — Pipeline Preclinical Data
A GLP-Compliant Toxicology and Biodistribution Study of ADVM-062 (AAV.7m8-L-opsin), a Novel Gene Therapy Product Being Developed as a Potential Single Intravitreal Administration for the Treatment of Blue Cone Monochromacy

Publications

Translational Vision Science & Technology
January 2021, Vol.10, 34
Long-Term Safety Evaluation of Continuous Intraocular Delivery of Aflibercept by the Intravitreal Gene Therapy Candidate ADVM-022 in Nonhuman Primates

Molecular Therapy – Methods & Clinical Development
Volume 18, Page 345-353
Analysis of aflibercept expression in non-human primates following intravitreal administration of ADVM-022, a potential gene therapy for neovascular age-related macular degeneration

ADVM-022 Clinical Data

Clinical Data Presentations

Macula Society 2022
Improved Anatomical Outcomes in ADVM-022 Treated Subjects Relative to Standard-of-Care Bolus Anti-VEGF Therapy: Results From the Phase 1 Study of Intravitreal (IVT) Gene Therapy with ADVM-022 for Neovascular AMD (OPTIC Trial)

ASGCT 2022
The OPTIC Study of Intravitreal Gene Therapy with ADVM-022 for Neovascular AMD (nAMD): The Role of Neutralizing Antibodies

ASGCT 2022
Non-Clinical Data Support Efficacy and Tolerability of a Human Equivalent Dose of 6E10 vg/eye of ADVM-022 for the Treatment of Neovascular Age-Related Macular Degeneration

ARVO 2022
New Data from the OPTIC Trial of ADVM-022: Role of Neutralizing Antibodies

AAO 2021
Encore Clinical Data from the INFINITY Trial of ADVM-022 Intravitreal Gene Therapy for DME

ASRS 2021
Encore Data from OPTIC Phase 1 Trial of ADVM-022 in Wet AMD – Cohorts 1-4

ASRS 2021
First Time Data from the INFINITY Trial of ADVM-022 Intravitreal Gene Therapy for DME

Retina Society 2021
New Data from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD – Cohorts 1-4

ASGCT 2021
Encore Data from OPTIC Phase 1 Trial of ADVM-022 in Wet AMD – Cohorts 1-4

ARVO 2021
New Clinical Data from OPTIC Phase 1 Trial of ADVM-022 in Wet AMD – Cohorts 1-4

Angiogenesis 2021
Encore Data from OPTIC Phase 1 Trial of ADVM-022 in Wet AMD – Cohorts 1-4

KOL/IR Discussion around AAO 2020
New Clinical Data from OPTIC Phase 1 Trial of ADVM-022 in Wet AMD – Cohorts 1-4

KOL/IR Discussion for 2Q20
New Clinical Data from OPTIC Phase 1 Trial of ADVM-022 in Wet AMD – Cohorts 1-4

KOL/IR Discussion around ARVO 2020
New Clinical Data from OPTIC Phase 1 Trial of ADVM-022 in Wet AMD – Cohorts 1-3

Angiogenesis, Exudation, and Degeneration Annual Meeting 2020
New Clinical Data from OPTIC Phase 1 Trial of ADVM-022 in Wet AMD – Cohorts 1&2

Atlantic Coast Retina Club Macula 20/20 Annual Meeting
New Clinical Data from OPTIC Phase 1 Trial of ADVM-022 in Wet AMD – Cohort 1

American Academy of Ophthalmology Annual Meeting 2019
New Clinical Data from OPTIC Phase 1 Trial of ADVM-022 in Wet AMD – Cohort 1

Retina Society Annual Meeting 2019
New Clinical Data from OPTIC Phase 1 Trial of ADVM-022 in Wet AMD – Cohort 1

Additional Research Presentations

Presentations and Posters

ASGCT 2022 – LSV1
Novel Capsid LSV1 Has a Unique 3D Structure at the Loop Substitution Area - Confers Superior Retinal Transduction from Intravitreal Injection

ASGCT 2022 – AAV.7m8 Platform
A GLP-Compliant Toxicology and Biodistribution Study of ADVM-062 (AAV.7m8-L-opsin), a Novel Gene Therapy Product Being Developed as a Potential Single Intravitreal Administration for the Treatment of Blue Cone Monochromacy

ARVO Annual Meeting 2021
Preclinical Evaluation of ADVM-062, a Novel Intravitreal Gene Therapy for the Treatment of Blue Cone Monochromacy

ARVO Annual Meeting 2020
Intravitreal Delivery of AAV2.7m8. Ranibizumab Suppresses Exudative Lesions in the NHP Laser Induced Model of nAMD

ARVO Annual Meeting 2020
Mouse Studies Support Intravitreal Gene Therapy for Blue Cone Monochromacy

ASGCT Virtual Annual Meeting 2020
Proof-of-Concept Studies in Mongolian Gerbils Support Intravitreal Gene Replacement Therapy of Human L-Opsin for Blue Cone Monochromacy

ASGCT Virtual Annual Meeting 2020
Large Scale Suspension Production of AAV Capsid Variant Libraries from Stable Recombinant HEK293 Cell Banks

ESGCT Annual Meeting 2019
In vivo screening of an adeno-associated virus capsid library in nonhuman primate eyes identifies a novel AAV variant with superior retinal penetration and transduction by intravitreal delivery

ESGCT Annual Meeting 2019
Biodistribution and pharmacokinetics of AAVRh.10-A1AT mediated gene therapy in humanized-liver mice as a predictor of A1AT human expression levels following intravenous delivery

ESGCT Annual Meeting 2019
Feasibility of Gene Therapy for Friedreich Ataxia Associated Cardiomyopathy in Non-Human Primates: Evaluation of Delivery Route, Biodistribution and Expression Following AAVRh.10-hFXN Administration

ARVO Annual Meeting 2018
Long-term functional delivery of the human L-opsin cDNA via intravitreal administration of an AAV vector in Mongolian gerbils

ARVO Annual Meeting 2017
Assessment of next-generation AAV variants in gerbil and non-human primate retina following intravitreal injection

ASGCT Annual Meeting 2017
Analysis of gene expression, tissue tropism, and safety of novel AAV variants in mice following intravenous administration